Changes in Hong Kong stocks | Insili Intelligence (03696) rose more than 3% at the end of the session and reached a multi-year anti-tumor drug research cooperation with Schweier

The Zhitong Finance App learned that Insili Intelligence (03696) rose more than 3% at the end of the session. As of press release, it had risen 2.89% to HK$38.46, with a turnover of HK$111 million.

According to the news, on January 5, Insilicon Intelligence announced that the group has reached a multi-year R&D cooperation with Schweier, a global independent pharmaceutical company managed by the Foundation. The partnership is worth 888 million US dollars. It will make full use of the artificial intelligence platform Pharma.ai independently developed by the Group to focus on challenging targets in the field of anti-cancer and identify and develop new therapeutic drugs. According to the agreement, the Group will be eligible for a down payment of up to 32 million US dollars and recent R&D milestone payments, and will lead the use of artificial intelligence technology platforms to discover and develop potential drug candidates that meet established standards, while Schweier will share R&D costs and lead the subsequent clinical trial and commercialization process.

It is worth mentioning that on December 30, 2025, Insilicon Smart officially landed on the main board of the Hong Kong Stock Exchange and was recognized by the market as the “first AI pharmaceutical stock” of the Hong Kong stock market. Its IPO performance was phenomenal: the Hong Kong public offering recorded an oversubscription of about 1,427 times, with a fixed subscription capital of over HK$328.3 billion; the international sale also had a strong response, recording a 26.27 times oversubscription. Both figures set the record for the highest number of non-18A Hong Kong healthcare IPOs during the year.